CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Instagram Outage Disrupts Thousands of U.S. Users 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TROY, Mich., Oct. 06, 2016 -- DirectRx Pharmacy, a leading independent pharmacy accredited by URAC, ACHC, NABP and WBENC, is one of only a few regional, specialty pharmacies selected to dispense SAMSCA, as part of their defined pharmacy network. SAMSCA is used to treat low sodium levels or hyponatremia.
The selection process for their defined pharmacy network was based upon high performance by DirectRx in areas including time to fill prescriptions, data interpretation and efficiency of procedures. These standards have also made DirectRx the recipient of the Specialty Pharmacy (SRX) accreditation by the ACHC and the URAC validation of excellence in Specialty Pharmacy Management in recent years.
SAMSCA is manufactured by Otsuka America Pharmaceutical, Inc. for the treatment of clinically significant hypervolemic and euvolemic hyponatremia, including patients with heart failure, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). It is considered a specialty medication and dispensed only by pharmacies proven to provide disease specific clinical monitoring as well as patient compliance and adherence programs.
“We are pleased to be selected as a distributor of a specialty medication such as SAMSCA, which requires carefully coordinated care between the patient, pharmacy and physician,” said Amanda Berishaj PharmD, of DirectRx. “At DirectRx, there are no gaps in patient care between physician and pharmacy because we believe that collaboration and communication are critical to creating favorable treatment outcomes. Our adherence programs assure that patients are regularly measured and monitored so that each one stays on their prescribed regimen and receives the support they need throughout the course of their treatment.”
An SRX dispenses medications which target a specific population with a chronic and sometimes life-threatening disease, including Crohn’s disease/ulcerative colitis, hepatitis C, HIV/AIDS, multiple sclerosis (MS), cancer, psoriasis and rheumatoid arthritis (RA). Specialty Pharmacy includes disease specific clinical monitoring as well as patient compliance and adherence programs.
DirectRx Pharmacy, an independent, family-owned pharmacy accredited by URAC, ACHC, NABP and WBENC, is dedicated to providing patients with unparalleled, personalized pharmaceutical care for their specialty pharmacy needs. Unlike other pharmacies, DirectRx is owned and operated by certified doctors of pharmacy. The company has grown to serve more than 38 states since its inception more than two decades ago. Investments in technology help to drive the best possible patient care and deliver the most accurate data to our partners. www.DirectRx.com
CONTACT: Amanda Berishaj, PharmD, DirectRx (248) 273-0480
